Drug Database
Back to search

United States· US:69489-411_52537ea0-9410-1691-e063-6394a90a9468

Qbrexza

A glycopyrronium product containing glycopyrronium tosylate, registered in United States by Journey Medical Corporation. The same ATC class is registered in 14 of our 19 countries.

ATC D11AA01US label

Checked against FDA National Drug Code directory (United States) on

Informational only — not a medical device.

SOURCE REGISTER · USFDA National Drug Code directory (Unite…normalisedQbrexzaATCD11AA01REGISTER NO.US:69489-411_52537ea0…PACKS LISTED4CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about glycopyrronium tosylateAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Glycopyrronium is registered in 14 of 19 countries.

Countries holding a registration under ATC D11AA01 (glycopyrronium), each read from that country’s own register.

  • This record: United States, from FDA National Drug Code directory (United States)
  • 8 of them publish a price we can compare per daily dose
Search glycopyrronium products by name

Glycopyrronium · ATC D11AA01

14 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FDA National Drug Code directory (United States)
Active substance
GLYCOPYRRONIUM TOSYLATE
Manufacturer
Journey Medical Corporation
Country
United States (US)
ATC code
D11AA01
ATC class
Glycopyrronium
Defined daily dose
8.8 mg, T
Reimbursed
Not published by this register
Source register
FDA National Drug Code directory (United States)
Last checked
September 27, 2026

Packs & prices · 4

  • ndc11
    6948941105
    5 POUCH in 1 CARTON (69489-411-05) / 2.8 g in 1 POUCH (69489-411-51)
  • ndc11
    6948941130
    30 POUCH in 1 CARTON (69489-411-30) / 2.8 g in 1 POUCH (69489-411-01)
  • ndc11
    69489-411-05
  • ndc11
    69489-411-30

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

108 interactions on record for glycopyrronium.

Graded by severity as the source publishes them — 107 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check glycopyrronium against other medicinesHow interaction checks work

Glycopyrronium · interactions on record

108 records

  • 107 moderate
  • 1 minor

Most severe, free to view

  • DicycloverineA03AA07moderate
  • PropanthelineA03AB05moderate
  • MepenzolateA03AB12moderate
  • TrospiumA03AB20moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Glycopyrronium in 11 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All glycopyrronium products

Authorised across Europe · EMA

The same active substance is authorised in 4 EEA countries. Names it is sold under:

  • Austria · Rybrila
  • Germany · Rybrila
  • Spain · Axhidrox
  • Sweden · Glycopyrronium Cantabria

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/1108ec28-a7bc-4c41-a671-564e1397c0da
GET /v1/drugs/1108ec28-a7bc-4c41-a671-564e1397c0da?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "route": "TOPICAL",
  "source": "ndc",
  "strength": "2.4",
  "substance": "GLYCOPYRRONIUM TOSYLATE",
  "productndc": "69489-411",
  "dosage_form": "CLOTH",
  "dea_schedule": null,
  "strength_unit": "g/100g",
  "application_number": "NDA210361",
  "marketing_category": "NDA"
}
API referenceMCP serverPlans

See everything about glycopyrronium.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console